Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Nov;181(5):1068-1070.
doi: 10.1111/bjd.18031. Epub 2019 Jul 18.

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series

Affiliations
Case Reports

Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series

Z N Willsmore et al. Br J Dermatol. 2019 Nov.
No abstract available

PubMed Disclaimer

References

    1. Simpson EL, Bieber T, Guttman-Yassky E et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-48.
    1. Blauvelt A, de Bruin-Weller M, Gooderham M et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389:2287-303.
    1. Summary of Product Characteristics (SmPC). Dupixent. Available at: https://www.medicines.org.uk/emc/product/8553 (last accessed 19 February 2019).
    1. Ou Z, Chen C, Chen A et al. Adverse events of dupilumab in adults with moderate-to-severe atopic. Int Immunopharmacol 2018; 54:303-10.
    1. Joosten LA, Lubberts E, Durez P et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40:249-60.

Substances